Table 1.
Characteristic features of study population in the discovery and validation cohorts.
|
Molecular Subtype TNBC |
Discovery 90 (100%) |
Validation 50 (100%) |
|
Gender Female |
90 (100%) |
50 (100%) |
| Age (Median) | 23–74 (53) | 26–73 (44) * |
|
Stage NA I II III |
2 (2.2%) 12 (13.3%) 54 (60%) 22 (24.5%) |
9 (18.0%) 4 (8.0%) 29 (58.0%) 8 (16.0%) |
|
NAC Taxane-based chemotherapy |
90 (100%) |
50 (100%) ** |
|
Response to NAC RD pCR |
38 (42.2%) 52 (57.8%) |
29 (58.0%) 21 (52.0%) |
NAC: neoadjuvant chemotherapy; RD: residual disease; pCR: pathological complete response. * Age information for 9 patients not available. ** Type of chemotherapy not indicated.